Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gynalac
- Development stage
- Unknown
- Lead developer
- Tyros Biopharma
- Modality
- Small Molecules
- Administration
- Vaginal
01
Overview
Gynalac is an over-the-counter, non-antibiotic vaginal gel developed by Tyros Biopharma. It is formulated as a combination of DL-lactic acid and sodium hyaluronate, designed to regulate and maintain normal vaginal pH (typically 3.8–4.5) and moisturize the vaginal mucosa. By acidifying the vaginal environment, Gynalac helps reduce pathogenic bacteria and supports the proliferation of protective Lactobacilli. It is indicated for the relief of symptoms associated with bacterial vaginosis and nonspecific vaginitis, such as abnormal discharge, odor, itching, and dryness, as well as for preventing the recurrence of bacterial vaginosis and restoring vaginal pH following antibiotic therapy.
- Brand names
- Gynalac
- Other names
- lactic acid + sodium hyaluronate
Beyond the preview
Go deeper on Gynalac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gynalac.